AI Tool Detects Parkinson’s Up To 15 Years Early With 96% Accuracy

Translate to Spanish or other 102 languages!

Researchers developed an AI tool to predict Parkinson’s disease from blood samples. Image for illustration purposes
Researchers developed an AI tool to predict Parkinson’s disease from blood samples. Image for illustration purposes

Medical News Today

- Advertisement -
  • Researchers developed an AI tool to predict Parkinson’s disease from blood samples. 
  • The tool can predict Parkinson’s 15 years before symptom onset with 96% accuracy. 
  • The underlying technology could possibly be adapted for diagnosing other conditions. 

Parkinson’s disease is a neurodegenerative condition characterizedTrusted Source by unintended movements such as shaking, stiffness, and difficulty balancing. It is caused by the loss of nerve cells in the brain, leading to reduced levels of dopamine, which plays a key role in movement.

To read the full story on Medical News Today Follow the link below: 

https://www.medicalnewstoday.com/articles/ai-tool-detects-parkinsons-up-to-15-years-early-with-96-accuracy?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2023-05-18&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

How Dogs Benefit Mind and Soul

"Dogs are wonderful greeters. They're waiting for you to come home, and they're always happy to see you. In turn, this increases our feel-good hormones, like dopamine and serotonin,” explained Chivonna Childs, PhD.

Data Reveals US Illicit Fentanyl Use is Double That of Clinical Care

The largest study to date that quantifies and compares medical and illegal use of fentanyl in the United States suggests that illicit use is more than twice as common as medically based use. 

7 Crucial Caregiving Truths Families Often Overlook

If you clicked to read this story, or someone sent it to you, congratulations: You’re a caregiver.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.
- Advertisement -